MMRF CureCloud Research Initiative
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03657251 |
Recruitment Status :
Recruiting
First Posted : September 5, 2018
Last Update Posted : July 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Multiple Myeloma Smoldering Multiple Myeloma | Genetic: liquid biopsy |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 5000 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 5 Years |
Official Title: | The MMRF CureCloud Multiple Myeloma Research Initiative |
Estimated Study Start Date : | July 14, 2020 |
Estimated Primary Completion Date : | July 31, 2025 |
Estimated Study Completion Date : | July 31, 2026 |

Group/Cohort | Intervention/treatment |
---|---|
CureCloud Direct to Patient |
Genetic: liquid biopsy
Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up. |
- Collection and Analyses of Clinical Information and Peripheral Blood Samples [ Time Frame: 5 years ]Patients that have been diagnosed with Multiple Myeloma, or one of its precursor conditions to share their clinical information and blood samples to help scientists and researchers understand these conditions better. The study will use submitted blood samples to perform comprehensive research that will include, among others, genomic and immune characterization, as well as collect past and present medical records to combine and compare with the blood sample analysis.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients diagnosed with Multiple Myeloma or a known or suspected precursor condition to Multiple Myeloma.
- Patients have signed an online consent form
Exclusion Criteria:
- Patients who live outside the United States
- Patients with a diagnosis other than Multiple Myeloma or a known or suspected precursor to Multiple Myeloma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03657251
Contact: Jennifer Yesil, M.S. | 203-652-0237 | yesilj@themmrf.org |
United States, Massachusetts | |
Dana Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Irene Ghobrial, MD |
Principal Investigator: | Daniel Auclair, PhD | Multiple Myeloma Research Foundation |
Responsible Party: | Multiple Myeloma Research Foundation |
ClinicalTrials.gov Identifier: | NCT03657251 |
Other Study ID Numbers: |
MMRF-18-001 |
First Posted: | September 5, 2018 Key Record Dates |
Last Update Posted: | July 27, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Some data collected may be deposited into databases such as dbGAP and GDC. All identifiable information will be removed prior to submission so that the data cannot be linked to the participant in any way. The database of Genotypes and Phenotypes (dbGaP) and the he Genomic Data Commons (GDC) are databases developed by the National Cancer Institute (NCI) to archive and distribute the results of studies that have investigated the interaction of genotype and phenotype. Data submitted from this study to dbGAP and GDC will only be available through controlled access and restricted to cancer research studies. Any researcher requesting access to the data must formally apply and present a research study rationale for why they need access to the data. The data may also be submitted to other future database systems which will have similar access controls as dbGAP and GDC. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Multiple Myeloma Smoldering Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias |
Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Precancerous Conditions Hypergammaglobulinemia |